Slideshow

Odor Identification: Marker for Early Alzheimer Disease?

Author(s):

Veronica Hackethal, MD

OI may serve for research purposes as a simple and inexpensive indicator of evolving AD pathology. Details here.

Related Videos
Fernando L. Pagan, MD
Fernando L. Pagan, MD
Fernando L. Pagan, MD
Fernando L. Pagan, MD
Fernando L. Pagan, MD
Fernando L. Pagan, MD
James Beck, PhD
Kinsey McCartney, PA-C
Related Content
Antonella Macerollo, MD, PhD (Credit: LinkedIn)
April 29th 2025

MRI-Guided Focused Ultrasound Demonstrates Efficacy for Essential Tremor, But Effect Decreases Over Time

Isabella Ciccone, MPH
Special Episode: What Apomorphine Infusion Approval Means for Parkinson Disease Care
March 27th 2025

Special Episode: What Apomorphine Infusion Approval Means for Parkinson Disease Care

Marco Meglio
FDA Clears INTRABEAM 700 as Supportive Device for Intraoperative Radiation Therapy
April 29th 2025

FDA Clears INTRABEAM 700 as Supportive Device for Intraoperative Radiation Therapy

Marco Meglio
Episode 132: Aiding Diagnosis of Synucleinopathies Through SAAmplify-aSYN Biomarker Test
January 10th 2025

Episode 132: Aiding Diagnosis of Synucleinopathies Through SAAmplify-aSYN Biomarker Test

Marco Meglio
Phase 2 Findings Support Further Development of 5-HT1A Receptor Agonist NLX-112 in Parkinson Disease
April 25th 2025

Phase 2 Findings Support Further Development of 5-HT1A Receptor Agonist NLX-112 in Parkinson Disease

Marco Meglio
GENERATION HD2 Trial of Huntington Agent Tominersen Amended to Include Only Higher Dose
April 24th 2025

GENERATION HD2 Trial of Huntington Agent Tominersen Amended to Include Only Higher Dose

Marco Meglio
© 2025 MJH Life Sciences

All rights reserved.